Funding for this research was provided by:
Fogarty International Center (K43TW010698)
GlaxoSmithKline Africa Non-Communicable Disease (NCD) Open Lab (8111 uganda; 074 South Africa)
Welcome Trust intermediate Clinical Fellowship (101143/Z/13/Z)
Received: 17 May 2019
Accepted: 8 January 2020
First Online: 15 January 2020
Ethics approval and consent to participate
: We have obtained ethical approvals from the Uganda Virus Research Institute, Research Ethics Committee (UVRI-REC) the Uganda National Council for Science and Technology (UNCST), from the Malawi National Health Sciences Research Committee and the University of Witwatersrand Human Research Ethics Committee (Medical).We will obtain written informed consent from participants for the collection and analysis of genetic samples as well as iohexol testing and for the use of their clinical records for research purposes. We will seek approval for all study procedures including material transfer agreements from the respective ethical review boards. In case we diagnose medical conditions through study screening, we will refer the participants to appropriate medical facilities. We will refer participants found to have advanced CKD to appropriate nephrology services as directed by the study physicians in each centre.
: Not applicable
: The authors declare that they have no competing interests.